Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combivir and Kaletra metabolic effects in healthy HIV-negative volunteers
ACTRN12605000661673Phase 4Recruiting
- Sponsor
- University of New South Wales
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial comparing Kaletra + Combivir, Kaletra alone and Combivir alone (3 arms). Primary endpoint: Change in adipocyte genes related to mitochondrial and lipid metabolism. Started Nov 2004; status: recruiting.
02
Drugs
lamivudine + zidovudinelopinavir + ritonavir
Beyond the preview
Go deeper on ACTRN12605000661673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000661673.